ZURICH: European regulators said the benefits of using Johnson & Johnson's and AstraZeneca's COVID-19 vaccines outweigh risks, even as they added warning labels to both shots for extremely rare but potentially fatal blood clotting.
Of that total, 142 were in the European Economic Area out of more than 30 million AstraZeneca vaccine doses administered in Britain and the European Economic Area over the past three months. AstraZeneca, which is still delivering its vaccines, said it was"working to understand individual cases and"possible mechanisms that could explain these extremely rare events".The U.S. regulator has paused the use of J&J's single-dose vaccine"out of an abundance of caution" to ensure that the health care providers are aware of potential side effects and can plan for"proper recognition and management.
"Usually, an anticoagulant drug called heparin is used to treat blood clots," they said."In this setting, administration of heparin may be dangerous, and alternative treatments need to be given." German doctors and scientists investigating clotting associated with AstraZeneca shots have also said the heparin issue remains"unclear," and have recommended that medical professionals administer intravenous immunoglobulin plus anticoagulant.For AstraZeneca's shot, the EMA said in March that, on average, just 1.
Very very worried 😟
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Source: YahooSG - 🏆 3. / 71 Read more »
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »